Kidney Cancer Drugs Global Market Report 2023

Feb 2023| TBR607E| TBRC (Publisher)

Sample Report

Report Highlights

Including: 1) By Type: Renal Cell Carcinoma; Urothelial Carcinoma
2) By Product: Nexavar (Sorafenib); Sutent (Sunitinib); Afinitor (Everolimus); Votrient (Pazopanib); Avastin (Bevacizumab); Inlyta (Axitinib); Torisel (Temsirolimus); Proleukin (Aldesleukin)
3) By End Users: Hospitals; Clinics; Research Center
Covering: Bayer AG; Pfizer Inc.; Novartis International AG; Exelixis Inc.; F. Hoffmann-La Roche Ag

Kidney Cancer Drugs Global Market Report 2023 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on kidney cancer drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
Assess the Russia – Ukraine war’s impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
Measure the impact of high global inflation on market growth.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Description:
Where is the largest and fastest growing market for kidney cancer drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The kidney cancer drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

Report Synopsis

Report Metrics	Details
Base year considered	2022
Forecast period considered	2022-2032
Units considered	$ Billion
Segments covered	By Type, By Product, By End Users
Industry covered	Pharmaceuticals
Regions covered	Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Countries covered	Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA
Companies studied	Bayer AG; Abbott Laboratories; Pfizer Inc.; Novartis International AG; Exelixis Inc.; F. Hoffmann-La Roche Ag; Genentech Inc.; Glaxosmithkline Plc; Active Biotech; Amgen; Thermo Fisher Scientific Inc.; Bristol-Myers Squibb; Eisai; Roche; Cipla Limited; Onyx; Rosetta Genomics; Aveo Pharmaceuticals; Immatics Biotechnologies; Prometheus Laboratories; Argos Therapeutics; Myriad Genetics Inc.; NeoGenomics Laboratories; NanoString Technologies Inc.; Sysmex Corporation; Illumina Inc.; Quest Diagnostics Incorporated

Scope

Markets Covered:

By Type: Renal Cell Carcinoma; Urothelial Carcinoma; Others (Renal Sarcoma, Renal Lymphoma)
By Product: Nexavar (Sorafenib); Sutent (Sunitinib); Afinitor (Everolimus); Votrient (Pazopanib); Avastin (Bevacizumab); Inlyta (Axitinib); Torisel (Temsirolimus); Proleukin (Aldesleukin); Other Products
By End Users: Hospitals; Clinics; Research Center; Other End-Users

Companies Mentioned: Bayer AG; Pfizer Inc; Novartis International AG; Exelixis Inc; F. Hoffmann-La Roche Ag

Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA

Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time series: Five years historic and ten years forecast.

Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,

Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

Delivery format: PDF, Word and Excel Data Dashboard.

Table 1 : Global Historic Market Growth, 2017-2022, $ Billion
Table 2 : Global Forecast Market Growth, 2022-2027F, 2032F, $ Billion
Table 3 : Global Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Table 4 : Global Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Table 5 : Global Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Table 6 : Global Kidney Cancer Drugs Market, Split By Region, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Table 7 : Global Kidney Cancer Drugs Market, Split By Country, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Table 8 : Asia-Pacific, Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Table 9 : Asia-Pacific, Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Table 10 : Asia-Pacific, Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Table 11 : China, Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Table 12 : China, Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Table 13 : China, Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Table 14 : India, Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Table 15 : India, Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Table 16 : India, Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Table 17 : Japan, Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Table 18 : Japan, Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Table 19 : Japan, Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Table 20 : Australia, Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Table 21 : Australia, Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Table 22 : Australia, Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Table 23 : Indonesia, Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Table 24 : Indonesia, Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Table 25 : Indonesia, Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Table 26 : South Korea, Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Table 27 : South Korea, Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Table 28 : South Korea, Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Table 29 : Western Europe, Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Table 30 : Western Europe, Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Table 31 : Western Europe, Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Table 32 : UK, Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Table 33 : UK, Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Table 34 : UK, Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Table 35 : Germany, Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Table 36 : Germany, Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Table 37 : Germany, Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Table 38 : France, Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Table 39 : France, Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Table 40 : France, Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Table 41 : Eastern Europe, Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Table 42 : Eastern Europe, Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Table 43 : Eastern Europe, Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Table 44 : Russia, Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Table 45 : Russia, Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Table 46 : Russia, Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Table 47 : North America, Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Table 48 : North America, Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Table 49 : North America, Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Table 50 : USA, Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Table 51 : USA, Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Table 52 : USA, Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Table 53 : South America, Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Table 54 : South America, Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Table 55 : South America, Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Table 56 : Brazil, Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Table 57 : Brazil, Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Table 58 : Brazil, Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Table 59 : Middle East, Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Table 60 : Middle East, Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Table 61 : Middle East, Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Table 62 : Africa, Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Table 63 : Africa, Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Table 64 : Africa, Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Table 65 : Bayer AG Financial Performance
Table 66 : Pfizer Inc Financial Performance
Table 67 : Novartis International AG Financial Performance
Table 68 : Exelixis, Inc Financial Performance
Table 69 : F. Hoffmann-La Roche Ag Financial Performance

Figure 1 : Global Historic Market Growth, 2017-2022, $ Billion
Figure 2 : Global Forecast Market Growth, 2022-2027F, 2032F, $ Billion
Figure 3 : Global Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Figure 4 : Global Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Figure 5 : Global Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Figure 6 : Global Kidney Cancer Drugs Market, Split By Region, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Figure 7 : Global Kidney Cancer Drugs Market, Split By Country, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Figure 8 : Asia-Pacific, Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Figure 9 : Asia-Pacific, Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Figure 10 : Asia-Pacific, Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Figure 11 : China, Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Figure 12 : China, Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Figure 13 : China, Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Figure 14 : India, Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Figure 15 : India, Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Figure 16 : India, Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Figure 17 : Japan, Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Figure 18 : Japan, Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Figure 19 : Japan, Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Figure 20 : Australia, Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Figure 21 : Australia, Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Figure 22 : Australia, Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Figure 23 : Indonesia, Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Figure 24 : Indonesia, Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Figure 25 : Indonesia, Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Figure 26 : South Korea, Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Figure 27 : South Korea, Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Figure 28 : South Korea, Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Figure 29 : Western Europe, Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Figure 30 : Western Europe, Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Figure 31 : Western Europe, Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Figure 32 : UK, Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Figure 33 : UK, Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Figure 34 : UK, Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Figure 35 : Germany, Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Figure 36 : Germany, Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Figure 37 : Germany, Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Figure 38 : France, Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Figure 39 : France, Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Figure 40 : France, Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Figure 41 : Eastern Europe, Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Figure 42 : Eastern Europe, Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Figure 43 : Eastern Europe, Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Figure 44 : Russia, Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Figure 45 : Russia, Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Figure 46 : Russia, Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Figure 47 : North America, Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Figure 48 : North America, Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Figure 49 : North America, Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Figure 50 : USA, Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Figure 51 : USA, Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Figure 52 : USA, Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Figure 53 : South America, Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Figure 54 : South America, Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Figure 55 : South America, Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Figure 56 : Brazil, Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Figure 57 : Brazil, Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Figure 58 : Brazil, Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Figure 59 : Middle East, Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Figure 60 : Middle East, Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Figure 61 : Middle East, Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Figure 62 : Africa, Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Figure 63 : Africa, Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Figure 64 : Africa, Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Figure 65 : Bayer AG Financial Performance
Figure 66 : Pfizer Inc Financial Performance
Figure 67 : Novartis International AG Financial Performance
Figure 68 : Exelixis, Inc Financial Performance
Figure 69 : F. Hoffmann-La Roche Ag Financial Performance

The Business Research Company is a market research and intelligence company which excels in company, market and consumer research. It has over 50 research professionals at its offices in India, the UK and the US as well a network of trained researchers globally. It has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services and technology.

Similar Reports from TBRC (Publisher)

Kidney Cancer Drugs Global Market Opportunities And Strategies To 2030: COVID-19 Growth And Change

Published Date - Jun 2022
Report Code - TBR607D

Including: 1) By Type: Renal Cell Carcinoma (RCC); Transitional Cell Carcinoma (TCC) Or Urothelial Cell Carcinoma (UCC)
2) By Product: Nexavar (Sorafenib); Sutent (Sunitinib); Afinitor (Everolimus); Votrient (Pazopanib); Avastin (Bevacizumab); Inlyta (Axitinib); Other Products
3) By End Users: Hospitals; Clinics; Research Center; Other End-Users
Covering: Pfizer Inc.; Novartis AG; Exelixis; Inc.; F. Hoffmann-La Roche AG; Bristol Myers Squibb Company

Kidney ...

Kidney Cancer Drugs Global Market Report 2022

Published Date - Mar 2022
Report Code - TBR607C

Including: 1) By Type: Renal Cell Carcinoma; Urothelial Carcinoma; Others (Renal Sarcoma, Renal Lymphoma)
2) By Product: Nexavar (Sorafenib); Sutent (Sunitinib); Afinitor (Everolimus); Votrient (Pazopanib); Avastin (Bevacizumab); Inlyta (Axitinib); Torisel (Temsirolimus); Proleukin (Aldesleukin); Others
3) By End Users: Hospitals; Clinics; Research Center; Others
Covering: Bayer AG; Pfizer Inc.; Novartis International AG; Exelixis Inc.; F. Hoffmann-La Roche Ag; Genentech Inc.; Glaxosmithkline ...

Kidney Cancer Drugs Global Market Report 2021: COVID-19 Impact And Recovery To 2030

Published Date - Jun 2021
Report Code - TBR607B

Including: 1) By Type: Renal Cell Carcinoma (RCC); Transitional Cell Carcinoma (TCC) or Urothelial cell carcinoma (UCC)
2) By Product: Nexavar (Sorafenib); Sutent (Sunitinib); Afinitor (Everolimus); Votrient (Pazopanib); Avastin (Bevacizumab); Inlyta (Axitinib); Torisel (Temsirolimus); Proleukin (Aldesleukin); Others
3) By End Users: Hospitals; Clinics; Research Center; Others

Covering: Bayer AG; Pfizer Inc; Novartis International AG; Exelixis; F. Hoffmann-La Roche Ag